Safety and Efficacy of NB-001 in 22q11DS Children with Anxiety, Inattention, and/or Autism

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The aim of this study is to determine if NB-001 (an investigational drug that is not approved by the FDA) is effective, safe, and well tolerated in treating children and adolescents with 22q11DS and anxiety, inattention, and/or autism. The study will take place over a 21-week period with routine telemedicine check-ins, home health nurse visits, and behavioral questionnaires. Except for the first visit which will be in-person at the CHOP Philadelphia campus, all other study visits will be done at the patient's home by a study nurse.

Eligibility & Criteria

IRB #:
21-018574
Official Title:
Safety and Efficacy of NB-001 in Children with 22q11.2 Deletion Syndrome and Associated ADHD- Anxiety, and Autism Spectrum Disorder
Study Phase:
Phase II
Eligible Age Range:
6 - 17 Years
Gender:
All
Study Categories:
Downloadable Resources:

Visit Criteria

Visits will involve:

  • Physical examinations, Bloodwork (screening visit will require fasting and optional genetic testing), ECG, Urine tests
  • Telemedicine call with the study doctor
  • Behavioral questionnaires and interviews with a psychologist

Leader

Madeline Chadehumbe